The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,435.00
Bid: 1,454.00
Ask: 1,456.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.138%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,435.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

16 Jul 2020 13:00

RNS Number : 2368T
Indivior PLC
16 July 2020
 

 

Indivior to Announce First Half and Second Quarter 2020 Results on July 30th and Host Conference Call Presentation

 

Slough, UK, and Richmond, VA, 16 July 2020 - Indivior PLC (LON: INDV) today announced that it will release its first half and second quarter 2020 results on July 30th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.

 

Key members of Indivior's leadership team led by Mark Crossley, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12:00 p.m. London time (7:00 a.m. U.S. Eastern).

 

Access the Live Webcast / Call for the Results on July 30th

The live webcast event will be available on the "Investors" section of the company's website at www.indivior.com. The webcast link is https://edge.media-server.com/mmc/p/ot3s33ij. Participants also may access the results presentation telephonically: US participants 1-631-510-7495; international participants +44 (0) 2071 928000. Please reference confirmation number 6735858. A replay of the presentation will be available at www.indivior.com.

 

About IndiviorIndivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

 

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NOREAEXKFEXEEFA
Date   Source Headline
14th Mar 20244:06 pmRNSDirector/PDMR Shareholding
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20242:00 pmRNSDirector/PDMR Shareholding
13th Mar 20241:09 pmRNSAnnual Financial Report
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20243:33 pmRNSHolding(s) in Company
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSDirector/PDMR Shareholding
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20245:01 pmRNSDirector/PDMR Shareholding
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSIndivior PLC Files 2023 Annual Report on Form 20-F
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20245:04 pmRNSDirector/PDMR Shareholding
6th Mar 20244:59 pmRNSDirector/PDMR Shareholding
6th Mar 20244:57 pmRNSDirector/PDMR Shareholding
6th Mar 20242:30 pmRNSDirector/PDMR Shareholding
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20242:53 pmRNSDirector/PDMR Shareholding
4th Mar 20249:35 amRNSDirector/PDMR Shareholding
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20249:27 amRNSTotal Voting Rights
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20247:00 amRNSTransaction in Own Shares
29th Feb 20247:00 amRNSFinal Court Approval Concludes Antitrust MDL
27th Feb 20241:32 pmRNSHolding(s) in Company
22nd Feb 20247:00 amRNSFinal Results
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 20247:00 amRNSTransaction in Own Shares
7th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 20247:00 amRNSTransaction in Own Shares
5th Feb 20247:00 amRNSTransaction in Own Shares
2nd Feb 20247:00 amRNSTransaction in Own Shares
1st Feb 20248:23 amRNSTotal Voting Rights
1st Feb 20247:00 amRNSTransaction in Own Shares
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20249:35 amRNSHolding(s) in Company
30th Jan 20247:00 amRNSTransaction in Own Shares
29th Jan 20247:00 amRNSTransaction in Own Shares
26th Jan 20245:37 pmRNSHolding(s) in Company
25th Jan 20242:30 pmRNSDirector/PDMR Shareholding - Correction

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.